greeksoup/ stock research

Roivant Sciences (ROIV) Q1 FY2025 earnings: revenue $2 million, down 72.8% on the year

Roivant Sciences Ltd. (ROIV) reported revenue of $2 million for Q1 FY2025, the quarter ended 30 June 2025, down 72.8% on the same quarter a year earlier. Net income was -$223 million, and diluted earnings per share $-0.33. The figures are the company's own, from the 10-Q it filed with the SEC on 11 August 2025.

Revenue$2 milliondown 72.8%
Net income-$223 million
Diluted EPS$-0.33
QuarterQ1 FY2025ended 30 June 2025

The quarter, against the one before and a year earlier

LineQ1 FY2025Q4 FY2024Q1 FY2024Change on the year
Revenue2.27.68.0-72.8%
Research and development153145121+26.9%
Selling, general and administrativen/an/a149n/a
Operating income-285-285-102n/a
Operating margin-13130.0%-3764.4%-1279.5%
Interest expensen/an/a13.4n/a
Pre-tax income-269-203-19.6n/a
Income tax4.649.312.0-61.1%
Net income-223-20695.3n/a
Net margin-10292.9%-2727.5%1192.7%
Diluted EPS-$0.33-$0.28$0.12n/a
$ million except per share.
Read moreFourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed.

Cash flow and capital returned

LineQ1 FY2025Q4 FY2024Q1 FY2024Change on the year
Operating cash flow-204-173-193n/a
Capital expenditure4.00.81.0+318.1%
Free cash flow-208-173-194n/a
Free cash flow margin-9604.5%-2290.3%-2425.5%
Cash from investing-1,0861,074-1.0n/a
Cash from financing-188-177-661n/a
Depreciation and amortisation1.11.44.9-77.5%
Share-based compensation82.283.550.2+63.7%
Buybacks208295648-67.9%
Diluted shares, weighted680m725m782m-13.0%
Shares outstanding at period end682m696m739m-7.7%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

LineQ1 FY2025Q4 FY2024Q1 FY2024Change on the year
Shareholders' equity4,3464,6885,435-20.0%
Non-controlling interest470500460+2.2%
Debt0.00.0312n/a
Operating lease liabilities90.390.345.9+96.9%
Other liabilities126159244-48.1%
Total liabilities and equity5,0335,4376,496-22.5%
Fixed assets14.912.117.8-16.7%
Intangible assetsn/an/a136n/a
Investments3,2652,171n/an/a
Cash and equivalents1,2382,7155,679-78.2%
Receivablesn/an/a79.8n/a
Inventoryn/an/a34.0n/a
Other assets515538550-6.5%
Total assets5,0335,4376,496-22.5%

Quarterly results, the last 12 quarters

Q2 FY2023 †Q3 FY2023 †Q4 FY2023 *Q1 FY2024 †Q2 FY2024Q3 FY2024Q4 FY2024 * †Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026
Revenue3.615.628.98.04.59.07.62.21.62.02.51.4
R&D115108121121143142145153165165199202
SG&A164197170149n/an/an/an/an/an/an/an/a
Operating income-2145,127-266-102-342-274-285-285-306-339415-366
Operating margin-5863%32949%-919%-1280%-7636%-3043%-3764%-13130%-19493%-16966%16478%-25381%
Interest expense9.29.47.213.4n/an/an/an/an/an/an/an/a
Pre-tax income-2415,154-191-19.6-224-235-203-269-159-290454-295
Tax raten/a0%n/an/an/an/an/an/an/an/a22%n/a
Net income-3045,096-15195.3-230169-206-223-114-266303-190
Net margin-8342%32748%-522%1193%-5144%1878%-2728%-10293%-7226%-13301%12024%-13165%
Diluted EPS-$0.40$6.03-$0.19$0.12-$0.31$0.23-$0.28-$0.33-$0.17-$0.38$0.34-$0.26
Operating cash flow-196-210-108-193-267-207-173-204-186-196-164-271
Capital expenditure0.30.40.31.01.01.80.84.07.8n/a1.30.4
Free cash flow-197-211-109-194-268-209-173-208-194n/a-165-271
Buybacks0.00.00.06481062432952080.00.0n/a207
Shares outstanding801m805m807m739m733m720m696m682m690m710m720m723m
Filing10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS and diluted share count are from the company's results press release for that quarter, used where the release gives the same revenue and net income as the table. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Source

10-Q for the period ended 30 June 2025, filed 11 August 2025, accession 0001140361-25-030001: the filing on EDGAR. All of Roivant Sciences Ltd.'s filings: EDGAR company page.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install